曲美他嗪治疗充血性心力衰竭的临床研究

目的观察曲美他嗪治疗充血性心力衰竭（CHF）的临床疗效。方法236例经常规洋地黄、利尿剂、血管扩张药等治疗效果欠佳的CHF患者,给予口服曲美他嗪20 mg,3次/日,治疗12周。观察治疗前后心率、心胸比、左室舒张末期内径、左室射血分数以及心功能变化。结果治疗后心率、心胸比以及左室舒张末期内径与治疗前比较均明显下降（P〈0.05）,左室射血分数增加（P〈0.05）,心功能改善1—2级。药物副作用少,患者耐受性好。结论曲美他嗪治疗CHF疗效好,副作用少,是比较理想的治疗药物。

The clinical study of Trimetazidine in treating congestive heart failure

Objective： To investigate the clinical study of Trimetazidine in treating congestive heart failure. Methods： 236 patients, who had unsatisfactory results under conventional Digitoras, Diuretics, Vasodilators therapy, were given Trimetazidine 20 mg orally 3 times a day for 12 weeks. The changes of heart rate （HR） , cardiothoracic ratio, left ventricular end diastolic diameter （LVDd） , left ventricular ejection fraction （LVEF） and cardiac function （NYHA） were observed. Results： After 12 weeks therapy, HR cardiothoracic ratio and LVDd all decreased significantly （P 〈 0.05 ） ; LVEF increased （ P 〈0.05 ） ; Cardiac function （NYHA） improved byl - 2 grade. Ibesartan had few adverse effects and patients tolerance was perfect. Conclusion： The effect of Trimetazidine in treating congestive heart failure is satisfactory and has few adverse effects. It is perfect for congesitive heart failure.